Junfeng Zhang

Junfeng Zhang

Auto-generated profile, based on publicly available information

Junfeng Zhang

Department of Urology, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JZJunfeng Zhang
Junfeng Zhang
QPQingyan Peng
Qingyan Peng
JFJin Fan
Jin Fan
FLFuzhong Liu
Fuzhong Liu
HCHongbo Chen
Hongbo Chen
PCPeng Chen
Peng Chen
Immune checkpoint inhibitors (ICIs) are a cornerstone therapy for advanced renal cell carcinoma (RCC). However, significant rates of primary resistance hinder their efficacy, and the underlying mechanisms remain poorly understood. This study aims to unravel the tumor-immune interactions and signaling pathways driving primary resistance to ICIs in RCC. We integrated single-cell RNA sequencing, spatial transcriptomics, and clinical sample analysis to investigate the tumor microenvironment and intercellular signaling. Advanced computational methods, including cell–cell communication networks, pseudotime trajectories, and gene set enrichment analysis (GSEA), were employed to uncover the underlying resistance mechanisms. Compared to the sensitive group, the primary resistance group exhibited a significant increase in SPP1-CD44 signaling-mediated interactions between tumor cells and immune cells. These interactions disrupted antigen presentation in immune effector cells and suppressed key chemokine and cytokine pathways, thereby impairing effective immune responses. In contrast, the sensitive group showed more active antigen presentation and cytokine signaling, which facilitated stronger immune responses. Furthermore, the interaction between SPP1-secreting tumor cells and CD44-expressing exhausted CD8 + T cells activated the MAPK signaling pathway within CD8 + Tex cells, exacerbating T cell exhaustion and driving the development of ICI resistance in RCC. Our findings reveal a potential mechanism by which SPP1-CD44 signaling mediates tumor-immune cell interactions leading to ICI resistance, providing a theoretical basis for targeting and disrupting this signaling to overcome primary resistance in RCC.

8 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JZJunfeng Zhang
Junfeng Zhang
FLFuzhong Liu
Fuzhong Liu
WGWenjia Guo
Wenjia Guo
XBXing Bi
Xing Bi
SYShuai Yuan
Shuai Yuan
PCPeng Chen
Peng Chen
Background: Aberrant intracellular or intercellular signaling pathways are important mechanisms that contribute to the development and progression of cancer. However, the intercellular communication associated with the development of ccRCC is currently unknown. The purpose of this study was to examine the aberrant tumor cell-to-cell communication signals during the development of ccRCC. Methods: We conducted an analysis on the scRNA-seq data of 6 ccRCC and 6 normal kidney tissues. This analysis included sub clustering, CNV analysis, single-cell trajectory analysis, cell–cell communication analysis, and transcription factor analysis. Moreover, we performed validation tests on clinical samples using multiplex immunofluorescence. Results: This study identified eleven aberrantly activated intercellular signaling pathways in tumor clusters from ccRCC samples. Among these, two of the majors signaling molecules, MIF and SPP1, were mainly secreted by a subpopulation of cancer stem cells. This subpopulation demonstrated high expression levels of the cancer stem cell markers POU5F1 and CD44 (POU5F1hiCD44hiE.T), with the transcription factor POU5F1 regulating the expression of SPP1. Further research demonstrated that SPP1 binds to integrin receptors on the surface of target cells and promotes ccRCC development and progression by activating potential signaling mechanisms such as ILK and JAK/STAT. Conclusion: Aberrantly activated tumor intercellular signaling pathways promote the development and progression of ccRCC. The cancer stem cell subpopulation (POU5F1hiCD44hiE.T) promotes malignant transformation and the development of a malignant phenotype by releasing aberrant signaling molecules and interacting with other tumor cells.

30 January 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
WPWei Peng
Wei Peng
HFHuan Feng
Huan Feng
LPLinhao Pang
Linhao Pang
JZJunfeng Zhang
Junfeng Zhang
YHYi Hao
Yi Hao
TWTao Wang
Tao Wang
Calcium/calmodulin-dependentprotein kinase II inhibitor I (CAMK2N1) as one of the tumor suppressor genes is significantly downregulated in prostate cancer (PCa). Reduced expression of CAMK2N1 is positively correlated with PCa progression. However, the mechanisms of CAMK2N1 downregulation in PCa are still unclear. The promoter region of CAMK2N1 contains a large number of CG loci, providing the possibility for DNA methylation. Consequently, we hypothesized that DNA methylation can result in the reduced expression of CAMK2N1 in PCa. In the presented study, the DNA methylation level of CAMK2N1 in prostate cells and clinical specimens was determined by bisulfite sequencing (BS), pyrosequencing, and in silico analysis. Results showed that CAMK2N1 was highly methylated in PCa cells and tissues compared to normal prostate epithelial cells and nonmalignant prostate tissues, which was associated with the clinicopathological characteristics in PCa patients. Afterwards, we explored the expression of CAMK2N1 and its DNA methylation level by qRT-PCR, western blot, BS, and methylation-specific PCR in PCa cells after 5-Aza-CdR treatment or DNMT1 genetic modification, which demonstrated that the reduced expression of CAMK2N1 can be restored by 5-Aza-CdR treatment via demethylation. Moreover, DNMT1 formed a positive feedback loop with CAMK2N1 in PCa cells. The expression of CAMK2N1 was downregulated by DNMT1-mediated DNA methylation, which reversely induced DNMT1 expression through activating AKT or ERK signaling pathway. Finally, functional assays including wound healing, invasion, and migration assay, as well as the xenograft model in nude mice indicated that CAMK2N1 inhibited the invasion, migration, and proliferation of PCa cells and these effects were reversed by DNMT1 overexpression. In conclusion, DNMT1-mediated hypermethylation of CAMK2N1 not only downregulates the gene expression but also promotes the progression of PCa.

16 December 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JZJunfeng Zhang
Junfeng Zhang
QPQingyan Peng
Qingyan Peng
FLFuzhong Liu
Fuzhong Liu
HCHongbo Chen
Hongbo Chen
XBXing Bi
Xing Bi
PCPeng Chen
Peng Chen
Background: Cancer stem cells (CSCs) are key contributors to treatment failure in clear cell renal cell carcinoma (ccRCC). Our prior single-cell RNA-seq analyses identified CSCs as the predominant source of SPP1, which may maintain stemness and promote progression via JAK1/STAT3 signaling, with POU5F1 as a putative upstream regulator. However, these SPP1-centered roles and their upstream/downstream mechanisms remain to be systematically validated. Methods: We integrated bioinformatics analysis with experimental validation using functional assays (proliferation, migration, tumorsphere formation), molecular mechanism studies (ChIP, Co-IP, dual-luciferase assays), and in vivo xenograft models to investigate the roles and mechanisms of SPP1. Results: In 30 paired tissues, POU5F1 and SPP1 were upregulated in ccRCC, and concurrent high expression in The Cancer Genome Atlas predicted poorer overall survival. In 786-O/769-P cells, loss- and gain-of-function experiments showed that either gene modulated proliferation, EdU incorporation, migration, and tumorsphere formation. SPP1 silencing reduced pJAK1/pSTAT3, whereas STAT3 blockade partially reversed SPP1-induced phenotypes. POU5F1 occupied the SPP1 promoter and increased promoter-driven transcription, leading to higher SPP1 expression and secretion; SPP1 knockdown attenuated POU5F1-overexpression effects. In xenografts, lowering POU5F1 or SPP1 decreased tumor growth, Ki-67, stem-like/EMT markers, and JAK1/STAT3 activity. Conclusions: Our findings support a POU5F1-SPP1- JAK1/STAT3 axis that sustains stem-like traits and malignant behavior in ccRCC. Targeting this axis may concurrently suppress bulk tumor cells and CSCs compartments, providing a biomarker-guided, dual-hit therapeutic rationale.